论文部分内容阅读
Objective: A secondary mutation in the EGFR (ie, T790M) and amplification of the c-Met proto-oncogene are the main causes of resistance to EGFR tyrosine kinase inhibitors (eg, gefitinib) in EGFRm+ NSCLC patients (pts).MSC2156119J is a highly selective, small-molecule c-Met inhibitor showing promising antitumor activity in a phase Ⅰ trial in pts with advanced solid tumors (Falchook et al.J Clin Oncol 2013:31[Suppl]:2506).